Morning Brief — July 28, 2026

Market Overview

Markets are navigating a sharp sector rotation as semiconductor stocks face pressure from China’s CXMT IPO and reports of domestic chip-making machine production, weighing on NVDA, MU, and SNDK. Enterprise software is the clear beneficiary of the chip selloff, with names like Workday, Shopify, and IQVIA surging on a combination of earnings beats and AI rotation narratives. The Fed decision looms as a backdrop, keeping the broader S&P near flat while the Nasdaq bleeds and the Dow holds up on non-tech strength.

Claude’s Call

FLAT — The S&P 500 likely grinds sideways to marginally lower today; the software-vs-chips rotation is a zero-sum trade within the index, and with the Fed decision ahead, institutional money won’t commit to a directional move — expect tight ranges with tech dispersion masking the flat tape.

Top Movers

FBRX (+39.65%) — $76.54 → $93.10 (+21.6% upside) Thesis: Clean, hard catalyst — argenx is acquiring Forte Biosciences in a $2.2B all-cash deal valued at roughly $20+/share premium, and FBRX is AT the 6-month high with no prior resistance above. The FB-102 anti-CD122 antibody program is the asset argenx is paying up for, suggesting genuine pipeline value rather than financial engineering. Deal closes Q3 2026, so the spread is the only game here — this is a merger arb situation now, not a momentum trade. Levels: Exit at $93.10 (fib 1.272 extension — that’s the deal price zone). Support at $62.18 (fib 23.6%) — but if the deal is real, you shouldn’t see it there.

Verdict: Legitimate acquisition catalyst, but at $76.54 you’re essentially buying deal spread risk. The upside is capped by the deal price; the downside is if argenx walks. Not a chase — this is for risk arb specialists only.

ITRI (+16.96%) — $99.16 → $113.06 (+14.0% upside) Thesis: Mixed earnings report — revenue actually MISSED by 7.2% YoY, but the EPS beat of 23.7% is doing all the heavy lifting here. The market is rewarding margin expansion over top-line miss, which tells you expectations were low and the cost structure is improving. ITRI broke decisively above its 50-day SMA ($83.28) and is approaching the 6-month high of $105.57 — this is a genuine breakout, not a gap-and-crap. Levels: Exit at $113.06 (fib 1.272 extension). Support at $99.07 (fib 23.6%), then $95.05 (fib 38.2%). The 50 SMA at $83.28 is your hard stop zone.

Verdict: The revenue miss is a yellow flag — guidance for $595M also came in 1.4% below consensus. The market is giving ITRI the benefit of the doubt on margins. Reasonable entry on a pullback to $99 fib support, but chasing the open gap is risky given the top-line softness.

SHOP (+11.54%) — $126.88 → $143.64 (+13.2% upside) Thesis: Pre-earnings positioning play — SHOP reports August 5, and management telegraphed “high-twenties” revenue growth guidance, which would be a meaningful acceleration. RBC’s new TCO model arguing SHOP has “great defensibility” against AI disruption is the analyst cover needed for funds to add. DoorDash native integration expands the merchant ecosystem further. RSI at 8.05 is technically extreme but likely data noise — the actual price structure shows SHOP bouncing off the 50 SMA ($114.77) and reclaiming the mid-range of the 6-month band. Levels: Exit at $143.64 (prior 6-month high — natural resistance). Support at $125.21 (fib 38.2%), then $114.77 (50 SMA — your stop reference).

Verdict: This has real legs IF the August 5 print delivers. “High-twenties” growth on a commerce platform fighting AI disruption fears is a genuine re-rating catalyst. The risk is you’re holding into earnings — sizing matters here.

IQV (+10.21%) — $235.00 → $265.66 (+13.1% upside) Thesis: Clean earnings BEAT — revenue +8.7% YoY to $4.37B beat by 1.6%, EPS of $3.15 beat by 3.9%, and full-year guidance raised to $17.38B midpoint (0.5% above consensus). IQVIA is showing that CRO demand is recovering, AI adoption in clinical trials is driving higher-margin work, and the drug launch pipeline is intact. The stock broke to a new 6-month high ($242.35) from a base at $156.66. RSI at 20.85 again looks like a data artifact — the price action is clearly bullish post-earnings. Levels: Exit at $265.66 (fib 1.272 extension). Immediate support at $222.13 (fib 23.6%) — that’s your first pullback level post-gap. Hard support at $209.62 (fib 38.2%).

Verdict: Justified reaction. This is exactly what a quality CRO stock should look like after a clean beat-and-raise quarter. The analyst target of $232 is already below current price — expect upgrades today. Buy-the-dip on any weakness toward $222.

WDAY (+9.01%) — $147.54 → $159.85 (+8.3% upside) Thesis: Pure sector rotation — chips selling off, enterprise software catching bids. No Workday-specific earnings or news today; this is 100% sympathy with Salesforce (+7%) and ServiceNow (+8%) as AI disruption fears for SaaS are being repriced lower. WDAY is bouncing from the $122-134 base range and the 50 SMA ($134.04) has been reclaimed. The 6-month range has a ceiling at $189.12 — there’s meaningful room before the stock is “full.” Levels: Exit at $159.85 (fib 38.2% retracement of the 6-month decline — key resistance). Support at $141.77 (fib 61.8%). Stop below $134.04 (50 SMA reclaim).

Verdict: Sector rotation trades are the weakest reason to buy — I’ll say it plainly. WDAY has no new fundamental catalyst today. This is a momentum-off-chip-weakness trade. It can continue if the software rotation has legs, but if chips stabilize, WDAY gives back half of this move. Don’t overstay.

RGEN (+9.61%) — $143.66 → $160.05 (+11.4% upside) Thesis: Solid earnings beat — EPS beat by 20%, revenue +11.9% YoY to $204.1M beat by 1.1%, and the $1.5B BioLife acquisition is expanding cell therapy capabilities. Full-year guidance of ~$824M is in line with estimates — management didn’t need to raise the bar, the operational beat did it. Repligen is a picks-and-shovels biopharma manufacturing play (filtration, chromatography, cell therapy tools) with secular tailwinds as drug makers scale biologics production. Levels: Exit at $160.05 (6-month high / prior resistance). Support at $138.21 (fib 38.2%), then $131.46 (fib 50% / aligns with 50 SMA at $131.45 — clean technical confluence).

Verdict: This is the highest-quality earnings catalyst on the board today. The BioLife deal adds a meaningful new revenue stream and RGEN’s role in biologics manufacturing is structurally growing. The 20% EPS beat on top of 11.9% revenue growth is impressive. This has legs.

UL (+8.39%) — $66.52 → $73.32 (+10.2% upside) Thesis: Unilever reported its best first-half sales growth in over a decade, upped full-year sales guidance, and is executing the Ice Cream/food business spin-off on schedule. This is a genuine fundamental catalyst in a consumer staples name that has been a defensive hiding spot. The stock is recovering toward its 6-month high of $73.32 from the $54.92 low — still 10% below the prior high with improving fundamentals. Levels: Exit at $73.32 (6-month high). Support at $66.29 (fib 38.2% — almost exactly current price, meaning you’re at support/resistance inflection). Below that, $64.12 (fib 50%) and the 50 SMA at $59.36.

Verdict: Rare case of a blue-chip consumer staples name with genuine upside. Best sales in a decade is not noise. With oil weak and defensive sectors outperforming, UL is in the right lane today.

Headlines to Watch

  • “AI Is Replacing Customer Service Jobs at CBA, Microsoft, Uber” (Bloomberg) — This is the structural death knell for CNXC/Concentrix — Bloomberg naming actual enterprise customers switching to AI for call centers confirms this isn’t fear, it’s reality. CNXC’s guidance cut last week now looks like the beginning, not the end.

  • “CXMT IPO Triggers Broad Semiconductor Selloff” — China’s state-backed memory chipmaker going public at scale is a supply overhang narrative for MU, SNDK, and NVDA — watch for continued pressure on SMH and whether the “AI infrastructure spend” thesis starts cracking at the edges.

  • “Shopify CEO calls pensioners ‘dependents’ who should lose voting rights” — Governance risk is real for SHOP; Tobi Lutke’s political commentary historically creates retail seller pressure. Headline risk into the August 5 earnings print — something to monitor.

  • “Unilever hails best sales in more than a decade ahead of food business spin-off” — Confirms the global consumer staples recovery narrative. Watch PG, KO, and UL peers for a catch-up trade if the defensive rotation continues alongside chip weakness.

  • “Thomson Reuters (TRI) Stock May Be Undervalued After AI Restructuring” — TRI is up 8.4% today with RSI at 10.59 — potentially deeply oversold bounce territory. The KKR deal for the Global Print business + AI restructuring narrative is underappreciated. Worth watching for a multi-week recovery trade.

  • “Software Is Beating Chips for Once. It May Not Be a Flash in the Pan.” — The WSJ piece validates today’s rotation narrative. If the AI investment thesis shifts from “build the picks and shovels” to “deploy AI in software,” IGV outperforms SOXX — this is the macro trade of the week.

  • “Fed Rate Decision This Week” — No one is going aggressively long or short ahead of the statement. The market’s FLAT disposition today is largely Fed-induced paralysis — any surprise (cut or hawkish hold) will be the real volatility event.

Claude’s Top Picks

IQV (+10.21% today, +16.56% week) — $235.00 → $265.66 (+13.1% upside) Valuation: No comps data available, but at $235 post-earnings on $17.38B full-year guidance, IQVIA trades at roughly 13-14x forward revenue — reasonable for a CRO with accelerating AI-driven margin expansion. Upside: Beat-and-raise quarter with full-year guidance above consensus; the CRO cycle is recovering, and IQVIA is the largest and most diversified player — institutional money will chase this upgrade cycle. Risk: The analyst target of $232 is already below current price, meaning a gap higher than what sell-side modeled — if the tape turns risk-off on the Fed, this could give back 5-8% quickly before finding support at $222.

RGEN (+9.61% today, +4.87% week) — $143.66 → $160.05 (+11.4% upside) Valuation: Biopharma manufacturing tools companies (Repligen, Sartorius, Cytiva peers) typically trade at premium multiples given secular biologics growth — RGEN’s 20% EPS beat suggests the market had this too cheap going in. Upside: The BioLife cell therapy acquisition adds a durable new revenue stream at scale, and the 11.9% organic revenue growth + 20% earnings beat gives management credibility to guide higher — expect multiple expansion as bioprocessing volumes continue recovering post-COVID destocking. Risk: Integration risk on the $1.5B BioLife deal is non-trivial; if cell therapy timelines slip, the acquisition premium looks expensive and RGEN re-rates to $131 support quickly.

SHOP (+11.54% today, +1.93% week) — $126.88 → $143.64 (+13.2% upside) Valuation: SHOP trades at a premium to SaaS e-commerce peers but the “high-twenties” revenue growth guidance — if confirmed August 5 — would be among the highest growth rates in large-cap software, making the premium defensible. Upside: Pre-earnings positioning with management pre-telegraphing strong Q2 growth, RBC upgrade with new TCO model, and DoorDash integration expanding the merchant TAM — three independent catalysts working simultaneously before the print. Risk: You’re holding into earnings on August 5 — any miss or guidance disappointment after an 11.5% single-day run will be punished harshly; position sizing must reflect the binary event risk.

UL (+8.39% today, +9.43% week) — $66.52 → $73.32 (+10.2% upside) Valuation: Unilever trades at a modest discount to peer Procter & Gamble on most metrics, and a “best sales in a decade” print with guidance raised should narrow that discount — the valuation is compelling for a defensive compounder. Upside: Fundamental earnings beat + defensive sector tailwind (oil weak, VIX elevated) + spin-off catalyst (Ice Cream business) creates a multi-layer setup that isn’t dependent on a single narrative. Risk: At $66.52 the stock is sitting right at the fib 38.2% support/resistance at $66.29 — if the broad market turns down on the Fed decision, UL may consolidate here rather than push to $73 in a straight line.

TRI (+8.44% today, +2.44% week) — $97.76 → $113.06 (+15.7% upside) Valuation: Thomson Reuters trades at a steep discount to its historical multiples after the 55.9% one-year decline — the KKR deal for Global Print and AI restructuring narrative suggests the selloff has been overdone relative to the underlying business quality. Upside: RSI at 10.59 signals a deeply oversold bounce setup; the stock is at the 50 SMA ($86.58) breakout zone after a multi-month washout, and the “AI restructuring undervalued” narrative is gaining traction with analysts — multiple expansion trade. Risk: The bear case is that AI genuinely disrupts Thomson Reuters’ core legal and financial data products; if that thesis holds, this is a value trap — the 55.9% decline was for a reason, and the bounce could fail at $99-100 resistance.

Avoid

FBRX — Trading at $76.54 at the 6-month high with the upside capped by the acquisition deal price; you’re buying pure merger arb spread risk at a stock that’s already up 40% today — the asymmetry is terrible for non-specialist investors.

WDAY — Up 9% on zero company-specific news; pure sector rotation sympathy trades historically give back 40-60% of the move within 48-72 hours when the rotation fades — no earnings catalyst, no guidance revision, no fundamental reason to own it above $150 when the 6-month high is $189 and there’s a gaping hole of overhead resistance.

TRAX (First Tracks Bio) — Up 18% to a 6-month high with the most recent relevant news being an analyst price target raise to $44 from back in July 10 — the catalyst is stale, volume is only 2% of average (vol_vs_avg: 0.02), and this looks like a thin-float squeeze in a small biopharma spinoff with no recent fundamental news. Chasing a 61% weekly gain on 2% of normal volume is a trap.

WSB Sentiment Check

MU — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — MU is trading below its 50 SMA ($958) at $833 and has broken through the fib 38.2% support at $872 with the CXMT IPO supply overhang now a real structural concern; the chart is in a downtrend from $1,213 and WSB is confusing “it’s down a lot” with “it’s a buy.”

SNDK — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — SNDK at $1,180 is in freefall from a $2,335 high, sitting below the 50 SMA ($1,723) and through major fib support at $1,217 — the CXMT competitive threat to NAND memory is existential, not cyclical, and catching this falling knife requires a thesis that Chinese oversupply gets resolved, which has no near-term catalyst.

NVDA — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — NVDA at $193.93 is below the 50 SMA ($207.70) and the China chip news is a legitimate overhang, but the long-term AI infrastructure buildout thesis remains intact; this is a case where WSB is right on the direction (eventually) but wrong on the timing — don’t chase here, wait for a reclaim of the 50 SMA.

SPCX — WSB says: BULLISH (80% bullish) Claude says: DISAGREE — SPCX at $108.54 is at a 6-month LOW (down from $211) with no 50 SMA (too new/recent), RSI not available, and whatever this SpaceX-adjacent vehicle is, it has lost 49% from highs — WSB is treating this as a mean-reversion play but there’s no support structure visible and it could be a product/narrative failure, not a dip.

MSFT — WSB says: BULLISH (80% bullish) Claude says: PARTIALLY AGREE — MSFT at $397.48 is clinging to the 50 SMA ($398.55) and is below the 6-month high of $479; the AI cloud narrative (Azure, Copilot) is real, but at a ~30x forward P/E with chip sector pressure as a headwind, the risk/reward is balanced not screaming buy — WSB’s 80% bullish read is justified on fundamentals, but the near-term technical setup is neutral, not a catalyst day.

Earnings Scorecard

CVLT (Commvault) — BEAT sales | Stock: -16.1% | Reported: Yesterday Beat revenue but the stock got demolished — classic “sell the news” on a name that had already run, with likely guidance disappointment or margin concerns overshadowing the top-line beat. Analyst target at $161 suggests this is a buy-the-dip for patient investors — the reaction looks overdone if guidance wasn’t catastrophically cut.

IQV (IQVIA) — BEAT +1.6% revenue, +3.9% EPS | Stock: +10.2% | Reported: Today Before Open Beat-and-raise quarter with full-year guide 0.5% above consensus — reaction is justified, this is exactly what the stock needed after a 6-month base. Not a sell-the-rip; the CRO recovery cycle is real.

RGEN (Repligen) — BEAT +1.1% revenue, +20.4% EPS | Stock: +9.6% | Reported: Today Before Open Clean beat with the EPS overshoot doing the work — reaction is justified and potentially insufficient given the magnitude of the EPS beat; this could grind higher into next week as funds adjust models.

BE (Bloom Energy) — EPS: -$0.04 | Stock: -9.1% | Reported: Yesterday Negative EPS in a high-expectation name after a 100%+ YTD run — this is a justified reaction; valuation was stretched and the miss confirms the “story stock” premium was overdone. Not a buy-the-dip until better fundamental visibility.

FFIV (F5 Networks) — EPS: $12.20, BEAT | Stock: -7.1% | Reported: Yesterday Beat earnings AND raised guidance per headlines, yet the stock dropped 7% — this is the most interesting divergence on the board. The market may be pricing forward multiple compression or read-through concerns. This reaction looks overdone and is potentially a buy-the-dip if guidance was genuinely raised; the $419 analyst target implies significant upside from current levels.

CNC (Centene) — BEAT, raised outlook | Stock: -6.7% | Reported: Yesterday Beat AND raised 2026 guidance, stock down 6.7% — the “negative payer mix shift” (rising uninsured) is the culprit, the same theme hitting HCA. This is a structural headwind, not a one-quarter issue. Sell-the-rip on bounces — the payer mix deterioration compounds forward.

KLAC (KLA Corp) — EPS: $3.54 | Stock: -6.0% | Reported: Yesterday Chip sector selloff amplified by CXMT overhang — KLAC’s -6% likely reflects sector contagion more than company-specific miss. With analyst target at $234 and semiconductor equipment as a structural play, this is likely overdone — watch for stabilization before stepping in.

CSGP (CoStar) — Stock: +4.4% | Reported: Yesterday Modest positive reaction in a beaten-down real estate data name — reaction is justified but insufficient if the earnings quality was solid. The soft real estate market has kept a ceiling on enthusiasm; track whether the print was actually strong or just “less bad.”

AMT (American Tower) — Stock: +3.8% | Reported: Yesterday Beat Q2 estimates but revenue outlook missed — the muted positive reaction (+3.8% on a beat with a miss outlook) is about right. Cell tower REITs are rate-sensitive; the Fed decision this week matters more than any single print. Hold, don’t chase.

All levels are derived from 6-month Fibonacci analysis. This brief is for informational purposes only and does not constitute financial advice. Trade your own risk.